Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Amgen Inc. (NASDAQ:AMGN) is also advancing xaluritamig, a first-in-class STEAP1 CD3 bispecific molecule, into Phase III clinical development for post-taxane metastatic castrate-resistant prostate ...

and Xaluritamig also entering phase 3 to treat metastatic castrate-resistant prostate cancer. PGIM Jennison Health Sciences Fund stated the following regarding Amgen Inc. (NASDAQ:AMGN) in its Q2 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...